The global CRISPR and CRISPR-associated (Cas) genes market is projected to grow rapidly, driven by advancements in gene editing, biotechnology applications, and expanding adoption in healthcare and agriculture.

The CRISPR and CRISPR-associated (Cas) Genes Market was valued at USD 3.03 Billion in 2024 and is expected to grow from USD 3.53 Billion in 2025 to reach USD 11.91 Billion by 2033, registering a CAGR of 16.4% during 2025–2033.

📥 Download Sample Report

CRISPR, short for clustered, regularly interspaced short palindromic repeats, is a natural defense system found in bacteria and archaea that protects against viral infections. When combined with Cas enzymes, particularly Cas9, it becomes a powerful gene-editing tool that enables precise DNA modifications. Today, CRISPR is revolutionizing biomedical research, biotechnology, agriculture, and therapeutic development.

Market Highlights

  • Products dominate the product and service segment

  • Biomedical applications lead the market share

  • Biotechnology and pharmaceutical companies remain the top end-users

  • North America is the largest regional market

Growth Factors

One major driver is the introduction of anti-CRISPR proteins, which improve safety and accuracy by reducing off-target effects in gene editing. This innovation expands potential applications in both basic and clinical research. Another growth driver is the expanding gene and cell therapy sector, where CRISPR is expected to play a central role in developing new treatments for genetic disorders.

Market Restraints

Despite its promise, CRISPR faces challenges with off-target effects, which can cause unwanted mutations. Ongoing research aims to improve precision through algorithmic advancements, protein engineering, and optimized guide designs.

Opportunities

The next decade is set to see significant breakthroughs in gene and cell therapy, with CRISPR at the forefront. Increasing investments, clinical trials, and regulatory progress are expected to create lucrative opportunities for industry players.

Regional Insights

  • North America leads the market, supported by government initiatives, CRISPR-based crop approvals, and biotech investments.

  • Asia-Pacific is witnessing strong growth, with China driving research in gene editing for medicine and agriculture.

  • Europe faces strict regulations but is progressing in biomedical and therapeutic applications.

  • Latin America is exploring CRISPR in GM crops and aquaculture, while MEA is gradually adopting the technology in healthcare and agriculture.

Key Players in the Market

  • AstraZeneca

  • Caribou Biosciences

  • Cellectis

  • Editas Medicine

  • Intellia Therapeutics

  • CRISPR Therapeutics

  • Precision Biosciences

  • Cibus

  • Lonza

  • Merck KGaA

Recent Developments

  • Jan 2023: ERS Genomics secured its first Canadian patent for CRISPR/Cas9 applications in humans, animals, plants, and microorganisms.

  • Mar 2023: Vertex Pharmaceuticals and CRISPR Therapeutics signed a non-exclusive licensing deal to accelerate the development of hypoimmune cell therapies for Type 1 Diabetes.

Market Segmentation

By Product and Service: Kits & Enzymes, Libraries, Design Tools, Antibodies, Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA Synthesis
By Application: Biomedical, Agriculture
By End-User: Biotechnology & Pharmaceutical Companies, CROs, Academic & Government Research Institutes
By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

About Us:

Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:

Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/